<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31734">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843218</url>
  </required_header>
  <id_info>
    <org_study_id>IB2008-07</org_study_id>
    <nct_id>NCT01843218</nct_id>
  </id_info>
  <brief_title>Erectile Rating During the Treatment of Rectal Cancers Localized</brief_title>
  <acronym>METEORR</acronym>
  <official_title>Erectile Rating During the Treatment of Rectal Cancers Localized. Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erectile dysfunction will be explored by recording R / P and self-administered questionnaire
      IIEF-5.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erectile dysfunction will be explored by recording R / P and self-administered questionnaire
      IIEF-5. This dual evaluation will be made before the beginning of the therapeutic treatment
      and 3 months and 12 months after surgery. Assessed by IIEF-5 will be made only 6, 18 and 24
      months after surgery. There will be no changes made ​​to support oncology patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>assess erectile dysfunction</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate objectively the presence of erectile dysfunction induced by medico-surgical treatment of rectal cancer three months after surgery. These objective data will be obtained using the Rigiscan ® PLUS system coupled to a polysomnogram. the investigators use the abbreviation Register R / P (Rigiscan ® PLUS / polysomonographie) in this protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe objectively and qualitatively erectile dysfunction before and 3 and 12 months after the medico-surgical management.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Rectal Cancer Stage I</condition>
  <arm_group>
    <arm_group_label>Register R</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation of erectile dysfunction in the management of localized rectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of erectile dysfunction</intervention_name>
    <description>Register R / P and self-administered questionnaire IIEF-5</description>
    <arm_group_label>Register R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male patient.

          2. Age greater than 18 years.

          3. Neoplastic rectal stage ≤ T3.

          4. Patient sexually active before diagnosis.

          5. Laparoscopic surgery.

          6. Medico-surgical institute Bergonié.

          7. Patient information and consent for participation in the study.

        Exclusion Criteria:

          1. Patients already treated for erectile dysfunction.

          2. Absence of sexual activity before diagnosis.

          3. Presence of secondary lesions at diagnosis (M +).

          4. Classified T4 tumor preoperatively.

          5. Surgery by laparotomy.

          6. History of pelvic cancer surgery prostate or bladder.

          7. History of pelvic radiotherapy (outside of the current process).

          8. History of prostate or bladder neoplasia known.

          9. Other neoplastic known.

         10. Patient for psychological, social, family or geographical could not be treated or
             monitored regularly according to the criteria of the study, patient deprived of
             liberty or under guardianship.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EVRARD Serge, PU-PH</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EVRARD SERGE, PU-PH</last_name>
    <email>s.evrard@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MATHOULIN PELISSIER Simone, PU-PH</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EVRARD SERGE, PU-PH</last_name>
      <email>s.evrard@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>EVRARD SERGE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.bergonie.org/fr/essais-clinique.html</url>
    <description>Site internet du promoteur, l'Institut Bergonié</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 26, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Localized rectal cancer in a male patient</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
